Background: Platelet activation results in platelet aggregation and the secretion of granules, which contain a variety of constituents including nonprotein molecules, adhesive proteins and hydrolases. The platelet-derived supernatant (PDS), which contains these granules, is known to trigger the activation of endothelium and chemotaxis of monocytes. Methods and Results: PDS derived from collagen-activated platelets stimulated human umbilical vein endothelial cell (HUVEC) migration and invasion, as measured through the use of a Boyden chamber. This collagen-induced PDS also triggered integrin αvβ3 upregulation in HUVECs. The inclusion of a neutralizing antibody to platelet-derived growth factor (PDGF)-B abolished HUVEC migration/invasion and integrin αvβ3 upregulation, showing that PDGF-AB mediates the proangiogenic effects of collagen-activated PDS. Saxatilin, a snake venom disintegrin known to interrupt platelet aggregation by antagonizing integrin αIIbβ3, inhibited the collagen-induced platelet activation and abolished the angiogenic properties of PDS. Saxatilin also inhibited the collagen-induced phosphorylation of Syk, a key mediator of inside-out signaling in platelet activation. Conclusion: Saxatilin inhibits platelet activation, platelet PDGF-AB release as well as subsequent endothelial cell migration and invasion.

Keywords:
Platelet, Saxatilin, Endothelial cell, Chemotaxis, Angiogenesis
1.
Andrews RK, Berndt MC: Platelet physiology and thrombosis. Thromb Res 2004;114:447–453.
2.
Gibbins JM: Platelet adhesion signalling and the regulation of thrombus formation. J Cell Sci 2004;117:3415–3425.
3.
Weyrich AS, Lindemann S, Zimmerman GA: The evolving role of platelets in inflammation. J Thromb Haemost 2003;1:1897–1905.
4.
Wagner DD, Burger PC: Platelets in inflammation and thrombosis. Arterioscler Thromb Vasc Biol 2003;23:2131–2137.
5.
Weber C: Platelets and chemokines in atherosclerosis: partners in crime. Circ Res 2005;96:612–616.
6.
Barry OP, FitzGerald GA: Mechanisms of cellular activation by platelet microparticles. Thromb Haemost 1999;82:794–800.
7.
Pinedo HM, Verheul HM, D’Amato RJ, Folkman J: Involvement of platelet in tumour angiogenesis? Lancet 1998;352:1775–1777.
8.
Janowska-Wieczorek A, Wysoczynski M, Kijowski J, Marquez-Curtis L, Machalinski B, Ratajczak J, Ratajczak MZ: Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int J Cancer 2005;113:752–760.
9.
Baj-Krzyworzeka M, Majka M, Pratico D, Ratajczak J, Vilaire G, Kijowski J, Reca R, Janowska-Wieczorek A, Ratajczak MZ: Platelet-derived microparticles stimulate proliferation, survival, adhesion, and chemotaxis of hematopoietic cells. Exp Hematol 2002;30:450–459.
10.
Gruber R, Karreth F, Kandler B, Fuerst G, Rot A, Fischer MB, Watzek G: Platelet-released supernatants increase migration and proliferation, and decrease osteogenic differentiation of bone marrow-derived mesenchymal progenitor cells under in vitro conditions. Platelets 2004;1:29–35.
11.
Rhee JS, Black M, Schubert U, Fischer S, Morgenstern E, Hammes HP, Preissner KT: The functional role of blood platelet components in angiogenesis. Thromb Haemost 2004;92:394–402.
12.
Brill A, Dashevsky O, Rivo J, Gozal Y, Varon D: Platelet-derived microparticles induce angiogenesis and stimulate post-ischemic revascularization. Cardiovasc Res 2005;67:30–38.
13.
Folkman J, Shing Y: Angiogenesis. J Biol Chem 1992;267:10931–10934.
14.
Ferrara N: Vascular endothelial growth factor: molecular and biological aspects. Curr Top Microbiol Immunol 1999;237:1–30.
15.
Hellstrom M, Kalen M, Lindahl P, Abramsson A, Betsholtz C: Role of PDGF-B and PDGFR-β in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 1999;126:3047–3055.
16.
Hirschi KK, Rohovsky SA, D’Amore PA: PDGF, TGF-β, and heterotypic cell-cell interactions mediate endothelial cell-induced recruitment of 10T1/2 cells and their differentiation to a smooth muscle fate. J Cell Biol 1998;14:805–814.
17.
Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J: Vascular-specific growth factors and blood vessel formation. Nature 2000;407:242–248.
18.
Eliceiri BP, Cheresh DA: Role of αv integrins during angiogenesis. Cancer J 2000;6:S245–S249.
19.
Eliceiri BP, Klemke R, Stromblad S, Cheresh DA: Integrin αvβ3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis. J Cell Biol 1998;140:1255–1263.
20.
Hood JD, Frausto R, Kiosses WB, Schwartz MA, Cheresh DA: Differential αv integrin-mediated Ras-ERK signaling during two pathways of angiogenesis. J Cell Biol 2003;162:933–943.
21.
Brooks PC, Clark RA, Cheresh DA: Requirement of vascular integrin αv β3 for angiogenesis. Science 1994;264:569–571.
22.
Kang IC, Chung KH, Lee SJ, Yun Y, Moon HM, Kim DS: Purification and molecular cloning of a platelet aggregation inhibitor from the snake (Agkistrodon halys brevicaudus) venom. Thromb Res 1998;91:65–73.
23.
Kang IC, Lee YD, Kim DS: A novel disintegrin salmosin inhibits tumor angiogenesis. Cancer Res 1999;59:3754–3760.
24.
Kim SI, Kim KS, Kim HS, Kim DS, Jang Y, Chung KH, Park YS: Inhibitory effect of the salmosin gene transferred by cationic liposomes on the progression of B16BL6 tumors. Cancer Res 2003;63:6458–6462.
25.
Hong SY, Koh YS, Chung KH, Kim DS: Snake venom disintegrin, saxatilin, inhibits platelet aggregation, human umbilical vein endothelial cell proliferation, and smooth muscle cell migration. Thromb Res 2002;105:79–86.
26.
Hong SY, Sohn YD, Chung KH, Kim DS: Structural and functional significance of disulfide bonds in saxatilin, a 7.7 kDa disintegrin. Biochem Biophys Res Commun 2002;293:530–536.
27.
Bellavite P, Andrioli G, Guzzo P, Arigliano P, Chirumbolo S, Manzato F, Santonastaso C: A colorimetric method for the measurement of platelet adhesion in microtiter plates. Anal Biochem 1994;216:444–450.
28.
Castellon R, Hamdi HK, Sacerio I, Aoki AM, Kenney MC, Ljubimov AV: Effects of angiogenic growth factor combinations on retinal endothelial cells. Exp Eye Res 2002;74:523–535.
29.
Heil M, Clauss M, Suzuki K, Buschmann IR, Willuweit A, Fischer S, Schaper W: Vascular endothelial growth factor (VEGF) stimulates monocyte migration through endothelial monolayers via increased integrin expression. Eur J Cell Biol 2000;79:850–857.
30.
Tan KT, Lip GY: The potential role of platelet microparticles in atherosclerosis. Thromb Haemost 2005;94:488–492.
31.
Rendu F, Brohard-Bohn B: The platelet release reaction: granules’ constituents, secretion and functions. Platelets 2001;12:261–273.
32.
Claesson-Welsh L: Mechanism of action of platelet-derived growth factor. Int J Biochem Cell Biol 1996;28:373–385.
33.
Woodard AS, Garcia-Cardena G, Leong M, Madri JA, Sessa WC, Languino LR: The synergistic activity of αvβ3 integrin and PDGF receptor increases cell migration. J Cell Sci 1998;111:469–478.
34.
Schneller M, Vuori K, Ruoslahti E: αvβ3 integrin associates with activated insulin and PDGFβ receptors and potentiates the biological activity of PDGF. EMBO J 1997;16:5600–5607.
35.
You WK, Jang YJ, Chung KH, Kim DS: A novel disintegrin-like domain of a high molecular weight metalloprotease inhibits platelet aggregation. Biochem Biophys Res Commun 2003;309:637–642.
36.
Shattil SJ, Gao J, Kashiwagi H: Not just another pretty face: regulation of platelet function at the cytoplasmic face of integrin alpha IIb beta 3. Thromb Haemost 1997;78:220–225.
37.
Judge HM, Buckland RJ, Holgate CE, Storey RF: Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses. Platelets 2005;16:398–407.
38.
Ogawa T, Sugidachi A, Otsuguro K, Isobe T, Asai F: Platelet α-granule secretion and its modification by SC-57101A, a GPIIb/IIIa antagonist. Biochem Pharmacol 2002;63:1911–1918.
39.
Ilveskero S, Lassila R: Abciximab inhibits procoagulant activity but not the release reaction upon collagen- or clot-adherent platelets. J Thromb Haemost 2003;1:805–813.
40.
Massberg S, Mueller I, Besta F, Thomas P, Gawaz M: Effects of 2 different antiplatelet regimens with abciximab or tirofiban on platelet function in patients undergoing coronary stenting. Am Heart J 2003;146:E19.
41.
Klinkhardt U, Kirchmaier CM, Westrup D, Breddin HK, Mahnel R, Graff J, Hild M, Harder S: Differential in vitro effects of the platelet glycoprotein IIb/IIIa inhibitors abixicimab or SR121566A on platelet aggregation, fibrinogen binding and platelet secretory parameters. Thromb Res 2000;97:201–207.
42.
Canobbio I, Balduini C, Torti M: Signalling through the platelet glycoprotein Ib-V-IX complex. Cell Signal 2004;16:1329–1344.
43.
Andrews RK, Lopez JA, Berndt MC: Molecular mechanisms of platelet adhesion and activation. Int J Biochem Cell Biol 1997;29:91–105.
44.
Chen H, Kahn ML: Reciprocal signaling by integrin and nonintegrin receptors during collagen activation of platelets. Mol Cell Bio 2003;23:4764–4777.
45.
Cowan KJ, Law DA, Phillips DR: Identification of Shc as the primary protein binding to the tyrosine-phosphorylated β3 subunit of αIIbβ3 during outside-in integrin platelet signaling. J Biol Chem 2000;275:36423–36429.
46.
Inoue O, Suzuki-Inoue K, Dean WL, Frampton J, Watson SP: Integrin α2β1 mediates outside-in regulation of platelet spreading on collagen through activation of Src kinases and PLCγ2. J Cell Biol 2003;160:769–780.
47.
Falati S, Edmead CE, Poole AW: Glycoprotein Ib-V-IX, a receptor for von Willebrand factor, couples physically and functionally to the Fc receptor γ-chain, Fyn, and Lyn to activate human platelets. Blood 1999;94:1648–1656.
48.
Poole AW, Gibbins JM, Turner M, van Vugt MJ, van de Winkel JG, Saito T, Tybulewicz VL, Watson SP: The Fc receptor γ-chain and the tyrosine kinase Syk are essential for activation of mouse platelets by collagen. EMBO J 1997;16:2333–2341.
49.
Pampolina C, McNicol A: Streptococcus sanguis-induced platelet activation involves two waves of tyrosine phosphorylation mediated by FcγRIIA and αIIbβ3. Thromb Haemost 2005;93:932–939.
50.
Watson SP: Collagen receptor signaling in platelets and megakaryocytes. Thromb Haemost 1999;82:365–376.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.